The present specification disclose a combined therapy comprising one or more activators of an alpha-7 nicotinic acetylcholine receptor activity having 5-HT.sub.3 receptor inhibitory activity and one or more activators of 5-HT.sub.3 receptor activity for use in treating a schizophrenic disorder as well as methods of treating a schizophrenic disorder by administering a combined therapy comprising one or more activators of an alpha-7 nicotinic acetylcholine receptor activity having 5-HT.sub.3 receptor inhibitory activity and one or more activators of 5-HT.sub.3 receptor activity.

This invention relates to novel method of treating or ameliorating a retinal disease or disorder or retinal degradation in a subject and a novel method of restoring retinal pigment epithelium cell compromising the administration of a one or more compounds which modulate Nox4, formation of radical oxygen species, serine protease, a dopamine receptor, NF-kB, mTOR, AMPK, RPE epithelial to mesenchymal transition, RPE dedifferentiation, or one or more Rho GTPases; and kits for administration of the methods.

Disclosed herein compositions of polysaccharides chemically cross-linked by aromatic dialdehydes. The compositions may be in form of polymeric sheets for a variety of applications. Disclosed also nano-sized particles comprising the polysaccharide chemically cross-linked by aromatic dialdehydes. The nano-sized particles may further comprise lipids and surfactants. Intranasal delivery of the nano-sized particles enables delivery of biologically active agents into the brain. Topical and transdermal delivery of the nano-sized particles enables delivery of biologically active agents for treatment of systemic or dermatological disorders. Methods of manufacturing and uses of the compositions are also disclosed.

The invention relates to the treatment of depressive and anxiety disorders, specifically to improved therapy for patients afflicted with post-stroke depression and/or anxiety, or with major depressive disorder. More specifically, the invention relates to the use of chemokine receptor (CCR5) inhibitors, either alone or in combination with antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), in treating depression and anxiety, as well as certain post-stroke complications that may include cognitive impairment. Compositions and methods according to embodiments of the invention are advantageously useful in the treatment of patients with treatment-resistant depression and other patient populations in which conventional antidepressant therapy is inadequate or insufficient.

The invention relates to the treatment of depressive and anxiety disorders, specifically to improved therapy for patients afflicted with post-stroke depression and/or anxiety, or with major depressive disorder. More specifically, the invention relates to the use of chemokine receptor (CCR5) inhibitors, either alone or in combination with antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), in treating depression and anxiety, as well as certain post-stroke complications that may include cognitive impairment. Compositions and methods according to embodiments of the invention are advantageously useful in the treatment of patients with treatment-resistant depression and other patient populations in which conventional antidepressant therapy is inadequate or insufficient.

The invention provides, FXR agonists for the treatment of a condition or a disease associated with mitochondrial dysfunction, e.g. a mitochondrial disease, in a subject in need thereof.

The invention provides, FXR agonists for the treatment of a condition or a disease associated with mitochondrial dysfunction, e.g. a mitochondrial disease, in a subject in need thereof.

The invention provides, FXR agonists for the treatment of a condition or a disease associated with mitochondrial dysfunction, e.g. a mitochondrial disease, in a subject in need thereof.

Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.